Patients with head and neck squamous cell carcinoma cancer are being recruited for participation in a research study involving experimental photoimmunotherapy.

IRB/UVA Tracking #
21271
Principal Investigator
Varinder Kaur
Contact
Olusegun Bamidele Adelaja
Contact Email
Contact Phone
804.527.4240
Official Trial Title
A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician’s Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or P
Study Description

The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults ages 18 and over, have head and neck squamous cell carcinoma cancer, and have tried at least 2 other methods of therapy that have not worked. The purpose of this study to evaluate the investigational combination of an experimental immunotherapy drug (ASP-1929) with an experimental medical laser device in patients with head and neck squamous cell carcinoma cancer. The safety and effects of the experimental drug combination will be evaluated for this study.

Participation is approximately 35 months or possibly longer. This includes screening, treatment, and follow-up periods. Study specific test will be provided at no cost to you.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT03769506

Compensation

You will receive up to $50 per visit.